Gland Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1785, down 2.46% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.02% on the day, quoting at 23521.8. The Sensex is at 77676.23, up 0.07%.Gland Pharma Ltd has gained around 0.55% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 0.59% in last one month and is currently quoting at 22868.1, down 1.9% on the day. The volume in the stock stood at 3.11 lakh shares today, compared to the daily average of 2.26 lakh shares in last one month.

The PE of the stock is 27.3 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1900.05, up 3.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.45% on the day, quoting at 24079.19921875. The Sensex is at 79453, down 0.61%. Gland Pharma Ltd has added around 5.51% in last one month.

Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 3.86% in last one month and is currently quoting at 23553.4, down 1.12% on the day. The volume in the stock stood at 3.67 lakh shares today, compared to the daily average of 1.73 lakh shares in last one month.

The PE of the stock is 27.52 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

In a regulatory filing made yesterday, the company stated that the Agence nationale de sécurité du médicament et des produits de santé (ANSM), France, conducted a good manufacturing practices (GMP) inspection of Cenexi’s Fontenay manufacturing facility (material subsidiary of Gland Pharma) between 9 to 19 of December 2024.

The said inspection was concluded, and the facility received an official notification on 24 December 2024, citing ten observations.

Cenexi is committed to working closely with the ANSM to address the observations,” Gland Pharma stated.

Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

On a consolidated basis, the firm’s net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24.

The scrip was up 0.62% to currently trade at Rs 1791 on the BSE.

Powered by Capital Market - Live News

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.

The approved drug is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.

The pharma company expects to launch this Product through its marketing partners in the near future.

According to IQVIA, the product had US sales of approximately $15 million for the twelve months ending September 2024.

Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

On a consolidated basis, the firm’s net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24.

Powered by Capital Market - Live News